MedTrace Logo

DIGITAL Biomarker: Blood Based Biomarkers in the Primary Care Setting for Alzheimer's Disease

NCT05844488 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2023-07-25

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the feasibility of implementing blood-based biomarker testing for amyloid positivity designed to aid the early detection of Alzheimer's Disease and Related Dementia (ADRD) in patients 65+ including the rate that patients and providers follow up abnormal blood-based biomarker testing.

Conditions

Interventions

DEVICE

PrecivityAD

Measure risk for amyloid plaques in the brain and will include a test for certain genetic variants (specifically, ApoE proteins in the blood revealing APOE genotype) known to be associated with Alzheimer's disease.

Sponsors & Collaborators

  • Davos Alzheimer's Collaborative

    collaborator UNKNOWN

  • Regenstrief Institute, Inc.

    collaborator OTHER

  • Indiana University

    lead OTHER

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-31
Primary Completion
2023-05-28
Completion
2023-06-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05844488 on ClinicalTrials.gov